URGO Group, through its Urgo Medical division, received the Prix Galien France 2018 in the medical device category for UrgoStart®, the first dressing to have demonstrated clinical efficacy in the treatment of chronic wounds, especially in diabetic foot ulcers
| PARIS, /PRNewswire/ -- URGO Group, through its Urgo Medical division, received the Prix Galien France 2018 in the medical device category for UrgoStart®, the first dressing to have demonstrated clinical efficacy in the treatment of chronic wounds, especially in diabetic foot ulcers. This prestigious award recognizes URGO’s work and investment in R&D and its ongoing commitment to innovating for patients. (Logo: https://mma.prnewswire.com/media/799815/Urgo_Invent_and_Care_Logo.jpg ) Urgo Medical: innovation as part of its DNA. URGO Group invests €25 million a year in R&D, in particular on medical technologies related to chronic wound healing. “The prestigious Prix Galien rewards six years of collective hard work. Our R&D teams have spared no effort in developing the innovative UrgoStart® wound dressing,” said a beaming Hervé Le Lous, Chairman of URGO Group. “Our goal is to enable many more people to heal much faster, which will be a major benefit for patients, doctors and nurses, and society as a whole.” UrgoStart®: a breakthrough in diabetic foot wound healing With close to 425 million people affected worldwide, diabetes has become an epidemic that is growing steadily [1]. Nearly one out of every four patients with diabetes will suffer from a diabetic foot ulcer at least once in their lifetime[2]. Such wounds are also a major risk of infection which can lead to amputation and even death. With one amputation carried out every 20 seconds, diabetes is the world’s leading cause of amputation[2]. In light of this finding, Urgo Medical launched the Explorer clinical study[3] in France, Spain, Italy, Germany and the UK, with the outcomes published in March 2018 in The Lancet Diabetes & Endocrinology. The results demonstrated the efficacy of UrgoStart® which led to a 60% increase in wound closure compared with standard care and reduced wound closure time by 60 days from an average period of 180 days. The first dressing to be deemed a local treatment, UrgoStart® is a French innovation recognized at the international level and now honoured by the Prix Galien. URGO Group: https://www.urgo-group.com/ Prix Galien France: https://www.prixgalien.fr/ 1. International Diabetes Federation. IDF Diabetes atlas. 8th ed. 2017. Brussels: International, International Diabetes Federation https://www.idf.org/e-library/epidemiology-research/diabestes-atlas.html 2. Whiting, D. R., Guariguata, L., Weil, C., and Shax, J. 23011. “IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030.” Diabetes Res. Clin. Pract. 94 (3):311-21 3. Michael Edmonds, José Luis Lázaro-Martínez, Jesus Manuel Alfayate-García, Jacques Martini, Jean-Michel Petit, Gerry Rayman, Ralf Lobmann, Luigi Uccioli, Anne Sauvadet, Serge Bohbot, Jean-Charles Kerihuel, Alberto Piaggesi. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol 2018;6 (3) :186-196 SOURCE URGO Group |
